Authors' reply

Affiliations

¹ W. Wolfgang Fleischhacker, Department of Psychiatry and Psychotherapy, Medical University Innsbruck, Austria. Email: wolfgang.fleischhacker@i-med.ac.at. Raymond Sanchez, MD, Otsuka Pharmaceutical Development & Commercialization, Princeton, USA.

Comment

W Wolfgang Fleischhacker et al. Br J Psychiatry. 2015 Feb.

. 2015 Feb;206(2):168-9.

doi: 10.1192/bjp.206.2.168a.

¹ W. Wolfgang Fleischhacker, Department of Psychiatry and Psychotherapy, Medical University Innsbruck, Austria. Email: wolfgang.fleischhacker@i-med.ac.at. Raymond Sanchez, MD, Otsuka Pharmaceutical Development & Commercialization, Princeton, USA.

No abstract available

Comment on

Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study.
Fleischhacker WW, Sanchez R, Perry PP, Jin N, Peters-Strickland T, Johnson BR, Baker RA, Eramo A, McQuade RD, Carson WH, Walling D, Kane JM. Fleischhacker WW, et al. Br J Psychiatry. 2014 Aug;205(2):135-44. doi: 10.1192/bjp.bp.113.134213. Epub 2014 Jun 12. Br J Psychiatry. 2014. PMID: 24925984 Clinical Trial.
The 'unknown' safety concern for aripiprazole once monthly.
Gupta SK, Kamboj A. Gupta SK, et al. Br J Psychiatry. 2015 Feb;206(2):168. doi: 10.1192/bjp.206.2.168. Br J Psychiatry. 2015. PMID: 25644886 No abstract available.